Pulmonary Arterial Hypertension Drugs Market Growth, Share, Size | Industry Report 2025

Healthcare

According to IMARC Group’s latest report, titled “Pulmonary Arterial Hypertension Drugs Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025,” the global pulmonary arterial hypertension (PAH) drugs market to continue its moderate growth during the next five years.

Pulmonary arterial hypertension (PAH) refers to a medical condition of high blood pressure in the arteries that connect the heart to the lungs. The symptoms of PAH are shortness of breath, dizziness, chest pressure, swollen legs, etc. In this case, the artery walls get narrow that exerts additional pressure on the heart to pump blood, thereby weakening the muscles. Various drug classes that are available for the treatment of pulmonary arterial hypertension include endothelin receptor antagonists (ERAs), vasodilators, phosphodiesterase-5 (PDE-5) inhibitors, soluble guanylate cyclase (sGC) stimulators, calcium channel blockers (CCBs), prostacyclin and prostacyclin analogs, etc.

Request for a free sample copy of this report:
https://www.imarcgroup.com/pulmonary-arterial-hypertension-drugs-market/requestsample

Market Trends

The rising geriatric population who are more prone to several cardiovascular disorders is primarily driving the demand for PAH drugs. Furthermore, the high prevalence of hypertension and high blood pressure due to sedentary consumer lifestyles, excessive alcohol consumption, lack of physical activities, unhealthy dietary patterns, etc., is also propelling the product demand. Moreover, the growing consumer awareness towards the wide presence of effective PAH drug-based therapies will continue to bolster the market growth in the coming years.

Pulmonary Arterial Hypertension Drugs Market 2020-2025 Analysis and Segmentation:

Breakup by Drug Class:

  1. Endothelin Receptor Antagonists (ERAs)
  2. Vasodilators
  3. Phosphodiesterase-5 (PDE-5) Inhibitors
  4. Soluble Guanylate Cyclase (sGC) Stimulators
  5. Calcium Channel Blockers (CCBs)
  6. Prostacyclin and Prostacyclin Analogs
  7. Others

Breakup by Route of Administration:

  1. Inhalation
  2. Injectable
  3. Oral Administration

Breakup by End User:

  1. Hospitals
  2. Clinics
  3. Others

Explore full report with table of contents: https://www.imarcgroup.com/pulmonary-arterial-hypertension-drugs-market

Breakup by Region:

  1. North America
  2. Asia Pacific
  3. Europe
  4. Latin America
  5. Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Actelion Pharmaceuticals Ltd (Johnson & Johnson), Arena Pharmaceuticals Inc., AstraZeneca PLC, Bayer Aktiengesellschaft, Daiichi Sankyo Company Limited, Gilead Science Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Pfizer Inc. and United Therapeutics Corporation.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

Contact US:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Website: https://www.imarcgroup.com/
Email: sales@imarcgroup.com
USA: +1-631-791-1145
Follow us on twitter: @imarcglobal
Linkedin: https://www.linkedin.com/company/imarc-group

Leave a Reply

Your email address will not be published. Required fields are marked *